Lifecore director granted 25,907 RSUs

Lifecore Biomedical director Nelson Obus received an equity grant in the form of restricted stock units.

Rhea-AI Filing Summary

Lifecore Biomedical director Nelson Obus received an equity grant in the form of restricted stock units. The award covers 25,907 RSUs that convert into common stock on a 1-for-1 basis. These units vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, provided that date is at least 50 weeks after June 4, 2026. Following this grant, Obus holds 164,100 shares of Lifecore Biomedical common stock directly.

Insider Trade Summary

Grant/Award: 25,907 shares

Grant/Award 1 txn

Insider OBUS NELSON

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,907	$0.00	$0.00

Holdings After Transaction: Common Stock — 164,100 shares (Direct)

Footnotes (2)

1. F1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
2. F2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Key Figures

RSU grant size: 25,907 units RSU conversion ratio: 1-for-1 into common stock Vesting milestone: June 4, 2027 +2 more

5 metrics

RSU grant size 25,907 units Restricted stock units granted to director Nelson Obus

RSU conversion ratio 1-for-1 into common stock Each RSU converts into one LFCR common share

Vesting milestone June 4, 2027 Vests on earlier of this date or 2027 annual meeting (≥50 weeks post June 4, 2026)

Shares held after grant 164,100 shares Direct common stock holdings following the RSU grant

Grant price per share $0.0000 Reported price per share for the RSU award

Key Terms

restricted stock units, convert into common stock, vests, annual meeting of stockholders

4 terms

restricted stock units financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

convert into common stock financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

vests financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

annual meeting of stockholders financial

"the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lifecore Biomedical (LFCR) director Nelson Obus report on this Form 4?

Nelson Obus reported receiving 25,907 restricted stock units of Lifecore Biomedical as a grant. These RSUs are a form of stock-based compensation and will convert into common shares on a 1-for-1 basis once they have vested under the stated conditions.

How many restricted stock units did Nelson Obus receive from Lifecore Biomedical (LFCR)?

Nelson Obus received 25,907 restricted stock units from Lifecore Biomedical. Each unit represents the right to receive one share of common stock when vested, effectively aligning the director’s compensation with future company performance and long-term shareholder interests.

When do Nelson Obus’s Lifecore Biomedical (LFCR) RSUs vest?

The RSUs vest on the earlier of June 4, 2027 or the date of Lifecore Biomedical’s 2027 annual stockholder meeting. That meeting date must be at least 50 weeks after June 4, 2026, establishing a clear service-based vesting schedule for the award.

What is the conversion ratio of Nelson Obus’s RSUs into Lifecore Biomedical (LFCR) common stock?

Each restricted stock unit converts into one share of Lifecore Biomedical common stock on a 1-for-1 basis. This means the 25,907 RSUs, once vested and settled, will result in 25,907 shares of common stock being issued to the reporting person.

How many Lifecore Biomedical (LFCR) shares does Nelson Obus hold after this RSU grant?

After the reported grant, Nelson Obus holds 164,100 shares of Lifecore Biomedical common stock directly. This figure reflects his direct ownership position following the award of the 25,907 restricted stock units reported in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OBUS NELSON

(Last) (First) (Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA MINNESOTA 55318

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		25,907	A	(1)(2)	164,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Remarks:

	/s/ Courtney Schuler, Attorney-In-Fact for Nelson Obus	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)